2 results
Not approvedWill not start
It is expected that LF111 will offer benefits to adults in the form of efficacy similar to COCPs, absence of estrogen-related risks, reduced tendency to weight gain and extended dosing window. It is likely that adolescents will share these benefits…
Approved WMOCompleted
to determine the normal FGF23 response in case of hypophosphatemia